The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel

Qian Liu1, Hao Zhang4,5, Lisa Smeester1, Fei Zou2, Matt Kesic3, Ilona Jaspers3, Jingbo Pi4, Rebecca C Fry1*

Abstract

**Background:** Drinking water contaminated with inorganic arsenic is associated with increased risk for different types of cancer. Paradoxically, arsenic trioxide can also be used to induce remission in patients with acute promyelocytic leukemia (APL) with a success rate of approximately 80%. A comprehensive study examining the mechanisms and potential signaling pathways contributing to the anti-tumor properties of arsenic trioxide has not been carried out.

**Methods:** Here we applied a systems biology approach to identify gene biomarkers that underlie tumor cell responses to arsenic-induced cytotoxicity. The baseline gene expression levels of 14,500 well characterized human genes were associated with the GI50 data of the NCI-60 tumor cell line panel from the developmental therapeutics program (DTP) database. Selected biomarkers were tested in vitro for the ability to influence tumor susceptibility to arsenic trioxide.

**Results:** A significant association was found between the baseline expression levels of 209 human genes and the sensitivity of the tumor cell line panel upon exposure to arsenic trioxide. These genes were overlayed onto protein-protein network maps to identify transcriptional networks that modulate tumor cell responses to arsenic trioxide. The analysis revealed a significant enrichment for the oxidative stress response pathway mediated by nuclear factor erythroid 2-related factor 2 (NRF2) with high expression in arsenic resistant tumor cell lines. The role of the NRF2 pathway in protecting cells against arsenic-induced cell killing was validated in tumor cells using shRNA-mediated knock-down.

**Conclusions:** In this study, we show that the expression level of genes in the NRF2 pathway serve as potential gene biomarkers of tumor cell responses to arsenic trioxide. Importantly, we demonstrate that tumor cells that are deficient for NRF2 display increased sensitivity to arsenic trioxide. The results of our study will be useful in understanding the mechanism of arsenic-induced cytotoxicity in cells, as well as the increased applicability of arsenic trioxide as a chemotherapeutic agent in cancer treatment.

**Background**

Arsenic poisoning is a global health issue and epidemiological studies indicate that chronic arsenic exposure in drinking water is linked to increased risk for various types of cancer [1-3]. More than 40 million people are exposed to drinking water with arsenic levels that far exceed the guideline established by the World Health Organization (WHO) and the limit acceptable by the US Environmental Protection Agency (EPA) of 10 ppb [4,5]. In contrast to its carcinogenic properties, arsenic trioxide can also be used as a clinically active agent to induce complete remission of acute promyelocytic leukemia (APL). The first clinical trial on arsenic trioxide treatment of relapsed APL patients after resistance to all-trans-retinoic acid (ATRA) treatment was carried out in China with a complete remission rate of 72% [6]. In another NCI-sponsored cancer and leukemia study, 77% of newly diagnosed APL patients who received combined chemotherapy and single arsenic trioxide

* Correspondence: rfry@unc.edu
1Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA
Full list of author information is available at the end of the article

© 2010 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
treatment remained in remission 3 years after diagnosis [7]. It is well accepted that arsenic trioxide results in apoptosis in multidrug resistant APL cells [8,9]. A primary mechanism associated with arsenic-trioxide’s effectiveness in treating APL is related to the ability to degrade and cleave the promyelocytic leukemia retinoic acid receptor-α (PML-RARα) oncoprotein [10]. As well, arsenic-induced apoptosis has been linked to the generation of hydrogen peroxide [11] and Bcl-2 down-regulation [12]. However, a comprehensive study examining the mechanisms and potential signaling pathways contributing to its anti-tumor properties has not been carried out.

In this research, we set out to identify gene biomarkers that are highly correlated with tumor cell responses to arsenic-induced cytotoxicity. The rationale was based on studies demonstrating that gene biomarkers can be used as predictors of tumor cell responses to therapeutic treatments [13,14]. The NCI-60 cell panel contains 60 human tumor cell lines that originate from nine different tumor types. Based on our systems biology analysis of the NCI-60 cell panel, we identified 209 human genes whose baseline expression levels were statistically associated with tumor cell susceptibility to arsenic trioxide. By integrating the gene biomarkers with known protein-protein networks, we show that the NRF2-mediated oxidative stress response pathway is significantly associated with tumor cell resistance to arsenic-induced cytotoxicity. Importantly, by generating tumor cells deficient for the expression of NRF2, we validate our computational approach designating NRF2 as a key regulator of arsenic trioxide resistance. Moreover, our results also indicate possible interactions between NRF2 and NFκB, which might contribute to the cellular resistance upon exposure to arsenic trioxide. Results from this study will help us to better understand the genes that influence the dual properties of arsenic trioxide as a human carcinogen and an effective chemotherapeutic agent.

Methods

In vitro arsenic trioxide screening data

The arsenic trioxide GI50 data were obtained from the Developmental Therapeutics Program (DTP) database at http://dtp.nci.nih.gov. The NCI-60 human tumor cell panel was used in the in vitro cell line screening project (IVCLSP) under the DTP program, where 59 cell lines in the NCI-60 cell panel were exposed to arsenic trioxide for 48 hours and growth inhibition of 50% (GI50) was recorded as the drug concentration resulting in a 50% reduction in the net protein increase in control cells during the drug incubation [15]. Cell lines were numbered from 1 to 59, corresponding to the increased cellular sensitivity to arsenic trioxide (Additional File 1).

Baseline gene expression data

The baseline gene expression data was from a previous publication [16] and the data are available online at http://discover.nci.nih.gov/. Using 59 cell lines of the NCI-60 human tumor cell panel, the investigators measured the baseline gene expression levels of 22,238 gene probes (representative of 14,500 human genes) using the Affymetrix HG-U133A chip [17].

Significance Analysis of Microarrays (SAM)

Significance analysis of microarrays (SAM) [18] was used to identify the association between the baseline gene expression levels and tumor cell responses (e.g. resistance or sensitivity) to arsenic trioxide. Specifically, SAM was used to identify statistically significant gene probes by carrying out gene specific t-tests and computing a score which measures the strength of the relationship between the expression of each gene (transcription profile) and the response variable (GI50). The use of permutation-based analysis accounts for correlations in genes and avoids parametric assumptions about the distribution of individual genes [19]. In this study, we set the false discovery rate (FDR) to 0.05 for declaring the significance of genes. According to data availability, 58 cell lines of the NCI-60 cell panel were included in our analysis - cell line 36 was excluded.

Network analysis and pathway mapping

Molecular network analysis and pathway mapping were carried out using the Ingenuity Knowledge Base http://www.ingenuity.com, a repository database of molecular interactions, regulatory events, gene-to-phenotype associations, and chemical knowledge [20]. With this systems biology tool, we integrated differentially expressed genes with known molecular networks. Networks are algorithmically generated based on their connectivity. The functional analysis of a network identifies the biological functions and/or diseases that are most significantly enriched in the network using a Fisher’s Exact test [21].

NRF2 knock-down cell generation and real-time RT-PCR validation

The A549 lung carcinoma tumor cell line (cell line #2 in Additional File 1) was used to generate cells deficient for the expression of NRF2 using short hairpin RNAs (shRNAs). Additionally, a control shRNA that has a scrambled sequence with no genome targeting, but that controls for the activation of RNAi machinery was also infected into the tumor cell line. For the lentiviral-based shRNA transduction, MISSION shRNA lentiviral particles were obtained from Sigma. The lentiviral transduction of A549 cells with particles for shRNAs targeting NRF2 (SHVRS-NM_006164), scrambled non-target
negative control (Scramble, SHC002V) or TurboGFP control (GFP, SHC003) was performed as described previously [22]. The cells were maintained in medium containing 3.0 μg/ml of puromycin. Knock-down of NRF2 was confirmed with real-time RT-PCR where expression was normalized to 18S. Primer sequences used to amplify NRF2 (NM-006164), NQO1 (NM_000903), β-ACTIN (X00351) and housekeeping gene 18 S (N87634) are as follows: (1) NRF2: forward (ACCGTG-GATCTGCAACTACTC) and reverse: (CTCGCGCCA AA GCTGCAT); (2) NQO1: forward (ACTGCCCCCTTT GTGTTGCAT) and reverse: (CTCGGTCTCAAT CCCTTCAT); (3) β-ACTIN: forward (GTCCACCTTC- CAGCAGATGTG); reverse (GCATTTCGGTGGAGC- GAT) and (4) 18S: forward (CGCCCCAGCAGCTTTG) and reverse (TTACCAGCCGATGGATGGA).

Cytotoxicity assays
To measure arsenic-induced cytotoxicity in the knockdown cells relative to control cells, a non-Radioactive Cell-Proliferation Assay Kit was used (Promega, Madison, WI). A minimum of 5 replicates of 10,000 cells per well were plated in 96-well plates and allowed to adhere to the plate for 24 hrs, at which time the media was removed and replaced with fresh media containing arsenic trioxide. Cells were then incubated for an additional 24 hrs and cell viability was determined. Measurements are expressed as percent of untreated control (vehicle) of appropriate cells. As a second method to assess arsenic-induced cytotoxicity, the enzyme lactate dehydrogenase (LDH) was measured in control or exposed cells. Cells were exposed in biological duplicate to inorganic arsenic across a dose range for 24 hrs and cytotoxicity determined using LDH release. Measurements were acquired using a coupled enzymatic assay according to the supplier’s instructions (Takara Bio Inc., Japan) and are represented as fold increase in LDH of NRF2-KD versus control.

Results
The baseline expression levels of 209 human genes are associated with tumor cell responses to arsenic trioxide
We set out to identify gene biomarkers of tumor cell responses to arsenic trioxide. Using data obtained from the DTP database [23], it is clear that the NCI-60 human tumor cell lines show differential cytotoxicity responses upon exposure to arsenic trioxide (see Methods; Figure 1; Additional File 1). The baseline gene expression data for the tumor cell lines were derived from a previous study [16]. The baseline gene expression levels of more than 14,500 well-characterized human genes were analyzed for the NCI-60 cell panel using the Affymetrix Human Genome Array U133A. Because of data availability, our study included 58 of the 60 human tumor cell lines.

To identify genes with expression levels associated with tumor cell susceptibility to arsenic trioxide, we applied a significance analysis of microarray (SAM) analysis [18] (see Methods). This resulted in the identification of 209 human genes (represented by 242 gene probes) whose baseline expression levels were statistically associated with tumor cell responses to arsenic trioxide (FDR < 0.05) (Figure 2; Additional File 2). Of the 209 genes, 169 genes had high expression in arsenic resistant tumor cell lines, whereas the other 40 genes had high expression in arsenic sensitive tumor cell lines.

Arsenic susceptibility genes are enriched for numerous biological processes including tumorigenesis
To identify biological processes associated with tumor cell responses to arsenic trioxide, we analyzed the 209 arsenic susceptibility-associated genes for network interactions (see Methods). A total of 188 of the 209 genes were eligible (e.g. present in the database) for network generation.

Through network mapping, we identified a large interactome associated with cellular response to arsenic trioxide (p < 10^-18), which contained a total 317 proteins (Figure 3A). This large interactome is enriched for biological processes related to tumorigenesis, including cancer, cell death, cellular movement, cell-to-cell signaling and interaction, cellular growth and proliferation, and tumor morphology (Additional File 3 and 4). Within this large arsenic-susceptibility-associated interactome, we identified 10 smaller, more focused sub-networks with p values < 10^-18. The top three sub-networks range in significance from p < 10^-37 to p < 10^-49, and they are enriched for 64 biological functions, among the most significant are cancer and cell death (Figure 3; Additional File 5).

The three sub-networks contain a total of 105 unique proteins. Of these, 70 were associated with tumor cell susceptibility to arsenic trioxide (Figure 3; Additional File 3). Within the 70 arsenic-susceptibility-associated proteins, 13 had high expression in arsenic-sensitive cell lines (19%) and 57 genes had high expression in arsenic-resistant cell lines (81%) (Additional File 3). Of these 70 proteins, 54 are associated with cancer, and 40 are associated with cell death (Figure 3).

The three sub-networks were found to be enriched for 18 transcriptional regulators (Table 1). Within these transcription factors, ID1 is known for its function in tumorigenesis [24] and also a possible therapeutic target for cancer treatment [25]. Other than these transcription factors, we also discovered protein complexes as integrated nodes in the three sub-networks that are associated with cellular response to arsenic-induced cytotoxicity, including activator protein 1 (Ap1) [26] and nuclear factor kappa B (NFκB) [27].
The NRF2-mediated oxidative stress response pathway shows increased expression in arsenic-resistant tumor cell lines

We next set out to identify the canonical signaling pathways that possibly underlie tumor cell responses to arsenic trioxide by applying pathway analysis to the 209 differentially expressed genes (see Methods). A total of 177 genes were eligible for canonical pathway analysis. The NRF2-mediated oxidative stress response pathway was the most significant canonical pathway enriched in this dataset (p < 10⁻³). This canonical pathway contains eight NRF2 target genes, whose baseline expression levels were statistically associated with arsenic susceptibility (Figure 4). Interestingly, all eight genes showed high expression levels in the arsenic-resistant tumor cell lines (Figure 4). The eight genes are: ATP-binding cassette sub-family C (CFTR/MPR) member 1 (ABCC1), ferritin heavy polypeptide 1 (FTH1), glutamate-cysteine ligase catalytic subunit (GCLC), glutathione reductase (GSR), NAD(P)H dehydrogenase, quinone 1 (NQO1), sequestosome 1 (SQSTM1), thioredoxin (TXN), and thioredoxin reductase 1 (TXNRD1).

Tumor cells deficient for NRF2 are sensitized to arsenic-induced cell killing

To validate the role of NRF2 in mediating cellular survival in response to arsenic treatment, we generated tumor cells (A549 lung carcinoma) that were deficient for NRF2 expression using shRNAs (see Methods). As controls, we also generated tumor cells that expressed a scrambled shRNA sequence that activates the RNAi machinery without inducing knock-down of NRF2. Cells were exposed to arsenic trioxide over a dose range and their differential survival assessed after 24 hours. The data demonstrate that cells that are deficient for NRF2 are sensitized to arsenic-induced killing (Figure 5; Additional File 6).

Discussion

In this study, we set out to identify gene biomarkers of tumor cell responses to arsenic trioxide-induced cytotoxicity. Using the cytotoxicity data established by the Developmental Therapeutics Program of the NCI, we ranked the tumor cell lines of the NCI-60 panel by their susceptibility to arsenic trioxide-induced killing. Through this ranking we find that there is a general trend of tumor cell susceptibility to arsenic trioxide for different tumor types. For instance, leukemia cell lines are distributed in the range of sensitivity to arsenic trioxide relative to the other tumor types. By associating the baseline gene expression levels of the NCI-60 human tumor cell panel with the arsenic trioxide-specific drug screening results, we identified 209 potential gene biomarkers with baseline expression levels that...
were significantly associated with tumor cell susceptibility to arsenic trioxide. Of the 209 genes, 169 (80.9%) were associated with arsenic resistance whereas the other 40 (19.1%) were associated with arsenic sensitivity. As expected, there is an association of the gene expression levels of these 209 genes with tumor type whereby many of same types of tumors show similar patterns of gene expression. As an example, in these analyses it is evident that the baseline gene expression levels of leukemia tumor cells with sensitivity to arsenic-induced killing are similar and cluster together. Likewise, colon tumor cells that show resistance to arsenic-induced killing also show baseline gene expression levels that are similar to each other, yet quite distinct from the leukemia tumor cell lines.

We applied a systems biology approach to examine these differentially expressed genes and affiliated networks and pathways, as well as the biological processes underlying tumor cell responses to arsenic-induced cytotoxicity. More specifically, in order to establish the potential biological mechanisms that underlie tumor cell responses to arsenic trioxide, we analyzed the 209 genes for known protein-protein interactions and enriched biological functions. We identified 64 common biological functions that were related to tumor cell responses to arsenic trioxide. Not surprisingly, we found that genes that are associated with arsenic susceptibility in the NCI-60 panel are statistically enriched for biological functions related to tumorigenesis, including cancer, cell death, cell-to-cell signaling and interaction, tumor morphology, and other functions relating to cancer disease.

We were intrigued to find numerous transcription factors with known links to tumorigenesis as well as with
known association to arsenic trioxide are among our most significant arsenic-susceptibility gene biomarkers. For example, the transcription factor ID1 is well known for its function in carcinogenesis [25,28]. Furthermore, a study has shown that the ID1 was induced by inorganic arsenite and may contribute to cell survival after exposure to sodium arsenite [29]. Our findings suggest a potential link between the expression level of this transcription factor and how tumor cells respond when exposed to arsenic trioxide.

By examining canonical pathways in the gene biomarkers, we identified the enrichment of the NRF2-mediated oxidative stress response pathway. Specifically, eight NRF2 target genes were identified as significantly associated and all eight target genes showed high expression in arsenic-resistant tumor cell lines. The NRF2 gene itself did not show an association of its baseline gene expression and arsenic susceptibility. These findings may indicate that the arsenic-resistant tumor cell lines express the same levels of NRF2 mRNA but with higher transcriptional activity compared to the arsenic sensitive cell lines.

Figure 3 Molecular interactomes and sub-networks associated with tumor cell susceptibility to arsenic trioxide. (A) A large arsenic-susceptibility interactome containing 317 proteins was identified. (B-D) The three most significant cancer and cell death enriched sub-networks within the large interactome were identified. Networks are displayed with symbols representing encoded proteins corresponding to their RNA transcripts that were either highly expressed in arsenic resistant cell lines (green symbols), highly expressed in arsenic sensitive cell lines (red symbols), or associated to the modified transcripts (white symbols). P-values representing the statistical significance of networks are shown.

Liu et al. BMC Medical Genomics 2010, 3:37
http://www.biomedcentral.com/1755-8794/3/37
Page 6 of 12
oxygen species (ROS) [31]. It has been a promising therapeutic target for various diseases [32-35] and recently linked to chemoprevention as well [14,36,37]. NRF2 works as a system with the protein Kelch-like ECH-associated protein 1 (KEAP1) [30]. Under normal conditions, NRF2 is bound by KEAP1 [38]. Exposure to NRF2-inducing agents results in the dissociation of NRF2 from KEAP1 and allows nuclear accumulation of NRF2, which triggers the expression of downstream target genes of NRF2 [30]. The NRF2 signaling pathway has been related to cell survival [39] and previous studies shown that NRF2 deficiency was associated with decreased rates on cell proliferation and tumor formation [40]. Interestingly, it has also been found that NRF2 and some of its downstream target genes were overexpressed in numerous tumor cell lines and human cancer tissues, which indicates its involvement in tumor formation [41-43]. NRF2 has also been shown to play a role in cellular responses to arsenic. For example, arsenic enhances the cellular expression of NRF2 at the transcript and protein levels and activates the expression of NRF2-related genes in skin cells [44]. In addition, arsenic-induced malignant transformation of human keratinocytes appears to require constitutive NRF2 activation [45].

To validate our computational prediction that NRF2 may mediate tumor cell survival in response to arsenic, we generated lung carcinoma cells that were deficient for the expression of NRF2. Through the computational analyses we predicted that cells with lower levels of NRF2 would be more sensitive to arsenic trioxide-induced killing. The results of the knock-down experiments support this and show that, as expected, cells that are deficient for NRF2 show increased sensitivity to arsenic-induced cytotoxicity. It should be noted the lung carcinoma cells that were used for these experiments are among the most resistant tumor cells of the NCI-60 panel to arsenic trioxide. It is therefore noteworthy that these highly resistant tumor cells can be altered to show increased cell killing to arsenic trioxide via their expression levels of NRF2.

Several of the NRF2 target genes identified from our study are of interest and support our findings in this work. For example, TXN and TXNRD1 are the key components of the thioredoxin system [46], which is an anti-oxidant system that has been linked to redox-induced cell death [47], cellular growth [48], and apoptosis [49]. Previous studies shown that the redox status of TXN determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death [50]. Moreover, research indicates that targeting the thioredoxin system to induce tumor cell apoptosis might underlie the anti-cancer mechanisms of several therapeutic agents, including arsenic trioxide [49].

ABCC1 is another noteworthy NRF2 target gene, and it is also known as multidrug resistance-associated protein 1 (MRP1). ABCC1 has been associated with chemotherapy resistance in several types of cancer [51], including cancers of the kidney [52], breast [53], and

| Table 1 Transcription factors identified within the sub-networks |
|---------------------------------------------------------------|
| **Transcription Factor** | **Description** | **Sub-network** |
| ELF3 | E74-like factor 3 | 1 |
| MTF2 | metal response element binding transcription factor 2 | 1 |
| ZEB1 | zinc finger E-box binding homeobox 1 | 1 |
| SMAD3 | SMAD family member 3 | 1 |
| KLF4 | Kruppel-like factor 4 (gut) | 1 |
| KLF5 | Kruppel-like factor 5 (intestinal) | 1 |
| CTBP2 | C-terminal binding protein 2 | 1 |
| GLI2 | GLI family zinc finger 2 | 1 |
| SQSTM1 | sequestosome 1 | 2 |
| ID1 | inhibitor of DNA binding 1 | 2 |
| HTATIP2 | HIV-1 Tat interactive protein 2, 30kDa | 2 |
| SMARCC1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 1 | 2 |
| ARID1A | AT rich interactive domain 1A (SWI-like) | 2 |
| MSX2 | msh homeobox 2 | 2 |
| IFIT16 | interferon, gamma-inducible protein 16 | 2 |
| JARID2 | AT rich interactive domain 2 | 2 |
| E2F3 | E2F transcription factor 3 | 2 |
| IRF6 | interferon regulatory factor 6 | 3 |

Table 1 lists the 18 transcription factors identified within the enriched sub-networks. The corresponding descriptions and locations within the sub-networks are included.
prostate [54,55]. ABCC1, as an ATP binding cassette protein, is believed to participate in chemotherapeutic agents transportation [51], including arsenic trioxide [56]; and possibly contributes to the chemoresistance in cancer treatment [51,57]. Chemotherapy resistance has been a huge obstacle in cancer treatment, and multidrug transporters like ABCC1 provide promising targets in chemotherapy [58-60] and valuable information for drug development. Our results indicate that ABCC1 could be a gene biomarker of arsenic response, as well as a potential chemotherapeutic target when using arsenic trioxide in cancer treatment, for APL and possibly other tumor types.

Another interesting finding is the identification of the transcription factor NFκB as an integrated node in the arsenic-susceptibility sub-network. NFκB is well known for its function in regulating genes for immune response, inflammation and apoptosis [61-63]. Numerous studies have shown that the NFκB signaling pathway is altered in the presence of arsenic trioxide [64-66]. For example, NFκB has been shown to be activated by arsenic at environmentally relevant concentrations [64,67-71] (reviewed in [72-74]). At higher doses, arsenic represses NF-κB activation [75]. The varied responses of NF-κB upon exposure to arsenic are certainly influenced by arsenic dose, arsenic species, and
cell type differences. Similar to NRF2, the baseline expression levels of NFκB were not statistically associated with tumor cell responses to arsenic trioxide. However, its transcriptional targets are. Previous studies have demonstrated the crosstalk between NRF2 and NFκB in biological processes including inflammation and carcinogenesis [76,77], but the interaction between these two transcription factors under cellular stress is not clearly understood. Our results suggest that NRF2 and NFκB both may contribute to tumor cell resistance upon exposure to arsenic trioxide, and the two transcription factors may work cooperatively in protecting tumor cells from arsenic-induced cytotoxicity.

Conclusions
In this study, we identified potential gene biomarkers of tumor cell responses to arsenic trioxide. These gene biomarkers have baseline expression levels that are statistically associated with tumor cell susceptibility to arsenic trioxide. Among the biomarkers are genes that are enriched for the NRF2 pathway. Using shRNA-mediated knock-down in a highly resistant lung tumor cell line, we show for the first time that deficiency for NRF2 in a tumor cell line results in increased sensitivity to arsenic trioxide. It may be the case that the other gene biomarkers are also potential modulators of cellular response to arsenic-induced cytotoxicity. The identification of the genetic factors such as NRF2 that underlie the tumor cell responses to arsenic trioxide will have direct implications in the continued application of arsenic trioxide as a chemotherapeutic agent in treating APL and other types of cancer. For example, these results can be applied for a better understanding of which tumor types will be responsive to arsenic treatment, thus facilitating the development of personalized medication.

Additional material

Additional file 1: GI50 of 59 cell lines of the NCI-60 human tumor cell panel. Lists the GI50 of 59 cell lines of the NCI-60 cell panel. Corresponding tumor type, cell line number, and cell line name are included. The cell lines were numbered from 1 to 59, according to
cellular sensitivity to arsenic trioxide (e.g. cell line number 1 is the most resistant cell line, whereas cell line 59 is the most sensitive cell line.)

Additional file 2: Potential gene biomarkers of tumor cell susceptibility to arsenic trioxide. Lists all the 242 gene probes (209 genes) that were statistically associated with tumor cell susceptibility to arsenic trioxide. Corresponding gene IDs, q-values, and gene descriptions are included.

Additional file 3: Gene products in network analysis. Lists all the 317 proteins contained within the large interactome. Each protein is listed as either its baseline expression level statistically associated with arsenic resistance/sensitivity, or it interacts with the directly associated transcripts. Corresponding gene symbols, gene names, gene IDs, and other relative information are included. Proteins within the three most significant sub-networks are also identified.

Additional file 4: 64 common biological functions enriched in arsenic susceptibility associated networks. Lists all the 64 biological functions enriched in arsenic susceptibility associated networks. The functional category, p-value, and arsenic susceptibility-associated molecules within these functions are included.

Additional file 5: Ten sub-networks within the large interactome. Lists the top ten sub-networks within the large interactome. Networks were built on the “Focus Molecules”, whose baseline expression levels are statistically associated with tumor cell susceptibility to arsenic trioxide. Molecules in the networks are either focus molecules (e.g. gene biomarkers of arsenic susceptibility) or molecules interact with them. P-values for the ten sub-networks are detailed.

Additional file 6: LDH release in NRF2 knock-down tumor cells. Lactate dehydrogenase (LDH) release was measured in NRF2 knock-down tumor (A549) cells (NRF2-KD) or control cells (expressing GFP reporter) exposed to inorganic arsenic.* indicates p < 0.05.

List of abbreviations
APL: acute promyelocytic leukemia; G50: Growth Inhibition of 50%; DTP: Developmental Therapeutics Program; NRF2: nuclear factor erythroid-2-related factor 2; WHO: World Health Organization; EPA: US Environmental Protection Agency; ppb - parts per billion; ATRA: all-trans-retinoic acid; NCI: National Cancer Institute; Bcl-2: B-cell CLL/Lymphoma 2; Nrf8: Nuclear Factor kappa B; SAM: Significance Analysis of Microarrays; FDR: False Discovery Rate; ELF3: E74-like factor 3; MTF2: metal response element binding transcription factor 2; ZEB1: zinc finger E-box binding homeobox 1; SMAD3: SMAD family member 3; KLF4: Krüppel-like factor 4; GCLC: glutamate-cysteine ligase catalytic subunit; GSR: glutathione reductase; MRP1: Multidrug Resistance-associated Protein 1; FTH1: ferritin heavy polypeptide 1; E2F3: E2F transcription factor 3; IRF6: interferon regulatory factor 6; Ap1 Activator Protein 1; ABCC1: ATP-binding cassette subfamily C interactive domain 2; E2F3: E2F transcription factor 3; ID1: inhibitor of DNA binding 1; HATATIP2: HIV-1 Tat interactive protein 2; 30kDa: 30 kDa; SAMC1: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c member; ARID1A: AT rich interactive domain 1A; GSH: glutathione; SOD1: superoxide dismutase; JARID2: jumonji, AT rich interactive domain 1B; MTF2: metal response element binding factor; SAM - Significance Analysis of Microarrays; FDR - False Discovery Rate; ELF3: E74-like factor 3; MTF2: metal response element binding transcription factor 2; ZEB1: zinc finger E-box binding homeobox 1; SMAD3: SMAD family member 3; KLF4: Krüppel-like factor 4; GCLC: glutamate-cysteine ligase catalytic subunit; GSR: glutathione reductase; MRP1: Multidrug Resistance-associated Protein 1; IFN: Interferon; NCI Cancer Bulletin: At a glance—cancer, chemotherapy, and stem cells in cancer drug discovery.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
QL performed the computational analysis and drafted the manuscript. HZ generated knock-down cells, performed cell killing assays and real time PCR LS performed arsenic-trioxide killing assays and assisted with manuscript preparation. FZ assisted with data analysis and interpretation. MK assisted with LDH assays. All assisted with manuscript preparation and oversaw LDH assays. JP oversaw knock-down experiments, RT-PCR analysis, killing assays and assisted with manuscript preparation. RF conceived and designed experiments, assisted with computational analysis, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This research was supported in part by grants from the National Institute of Environmental Health Sciences P30-E510126 (RF), ES016005 (JP) and the American Chemistry Council (ACC)-Long Range Research Initiative (JP). The content is solely the responsibility of the authors. J.P. is an employee of The Hamner Institutes for Health Sciences. The Hamner is a 501(c) 3 not-for-profit organization that has a diverse research portfolio that includes funding from the ACC, a trade association that represents chemical manufacturers.

Author details
1. Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
2. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.
3. Center for Environmental Health Sciences, Asthma, and Lung Biology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
4. The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA.
5. Department of Environmental Health, School of Public Health, Fudan University, Shanghai 200032, P.R. China.

Received: 15 March 2010 Accepted: 13 August 2010

Published: 13 August 2010

References
1. Lubin JH, Beame Freeman LE, Cantor KP: Inorganic arsenic in drinking water: an evolving public health concern. J Natl Cancer Inst 2007, 99(12):906-907.
2. Rahman MM, Ng JC, Naidu R: Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. Environ Geochem Health 2009, 31 Suppl 1: 189-200.
3. Guha Mazumder DN: Chronic arsenic toxicity & human health. Indian J Med Res 2008, 128(4):436-447.
4. Rahman MM, Chowdhury UK, Mukherjee SC, Mondal BK, Paul K, Lodh D, Biswas BK, Chanda CR, Basu GK, Saha KC, et al: Chronic arsenic toxicity in Bangladesh and West Bengal, India—a review and commentary. J Toxicol Clin Toxicol 2001, 39(7):683-700.
5. Mukherjee A, Bhattacharya P, Savage K, Foster A, Bundschuh J: Distribution of geogenic arsenic in hydrologic systems: controls and challenges. J Contam Hydrol 2008, 99(1-4):1-7.
6. Sun HD, Ma L, Hu X-C, Zhang T: Ah-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin & West Med 1992, 12:170-172.
7. NCI Cancer Bulletin: Arsenic trioxide improves survival in adults with APL. [http://www.cancer.gov/ncicancerbulletin/]
8. Chatterjee N, Choudhury UK, Mukherjee SC: Non-steroidal anti-inflammatory drugs differentially modulate gene expression of various detoxification enzymes in human lymphocytes. J Toxicol Environ Health A 2009, 72(14):1197-1206.
9. Rajewski MT, Korper S, Schrezenmeier H: Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma 2004, 45(12):2387-2401.
10. Ren J, Jiang Y, Zhao X, Lu Y, Chen Y, Guo J, Wang Z, Zhang H, Li J, Wang Z: A novel role for histone deacetylase 4 in arsenic trioxide resistance in chronic myeloid leukemia. Leukemia 2010, 24(8):1623-1631.
11. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenical compounds induce apoptosis in AML cells and enhance arsenic trioxide toxicity in AML cells. Leukemia 1999, 13:1871-1875.
12. Huang Y, Bhatnagar A, Kumar S, Buchholz AL, Duvic M, Zeleznik AJ, Denicola T, Thiele J, Arora A: Arsenic trioxide induces apoptosis and differentiation in acute promyelocytic leukemia cells. Leukemia 2009, 23(11):1988-1995.
13. Liu et al: BMC Medical Genomics 2010, 3:37 http://www.biomedcentral.com/1755-8794/3/37
resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008, 135(4):1358-1368, 1368 e1351-1354.
15. Almoghadam K: Arsenic trioxide and acute promyelocytic leukemia: a drug for all stages of disease. Clinical Leukemia 2008, 2(2):107-112.
16. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Monta D, Chary KK, Reimers MA, Scherf U, Kahn A, Doginow D, et al: Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007, 6(32):820-832.
17. Design and Performance of the GeneChip Human Genome U133 Plus 2.0 and Human Genome U133A 2.0 Arrays. [http://www.affymetrix.com]
18. Tuscher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98(9):5166-5171.
19. SAM “Significance Analysis of Microarrays” Users guide and technical document. [http://www.stat.fsu.edu/~tibs/SAM/sam.pdf]
20. Ingenuity Systems, Products & Services, Ingenuity Pathways Analysis (IPA), [http://www.ingenuity.com/products/pathways_analysis.html]
21. Jardim MJ, Fry RC, Jaquers I, Dailey L, Diaz-Sanchez D: Disruption of microRNA expression in human airway cells by diesel exhaust particles is linked to tumorigenesis-associated pathways. Environ Health Perspect 2009, 117(11):1745-1751.
22. Woods CG, Fu J, Xue P, Hou Y, Pluta LJ, Yang L, Zhang Q, Thomas RS, Andersen NEF: P13K-Akt-mTOR pathway: Dose-dependent transcription in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. Toxicol Appl Pharmacol 2009, 238(1):27-36.
23. Drug discovery at the national cancer institute: fact sheet. [http://www.cancer.gov/cancertopics/factsheet/ncc/drugdiscovery].
24. Maw MK, Fujimoto J, Tamaya T: Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumour advancement of ovarian cancers. BMC Cancer 2009, 9:340.
25. Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Frohling S, Wang A, Monti S, Meadows AJ, Wang H: SAM applied to the ionizing radiation response. Toxicol Appl Pharmacol 2008, 238(2):1981-1992.
26. Hwang BJ, Steinberg M: Induction of cyclin D1 by submicromolar concentrations of arsenite in human keratinocyte epithelial keratinocytes. Toxicol Appl Pharmacol 2006, 217(2):161-167.
27. Tun-Kyi A, Qin JZ, Oberholzer PA, Navarini AA, Hassel JC, Dummer R, Dogbeling U: Arsenic trioxide down-regulates antipotopotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol 2008, 19(8):1488-1494.
28. Yu X, Xu X, Han B, Zhou P: Inhibitor of DNA-binding-1 overexpression in prostate cancer: relevance to tumor differentiation. Pathol Oncol Res 2009, 15(1):91-96.
29. McNeely SC, Xu X, Taylor BF, Zacharias W, McCabe MJ Jr, States JC: Exit from arsenite-induced mitotic arrest is p53 dependent. Environ Health Perspect 2006, 114(9):1401-1406.
30. Osborn WO, Kessler TW: Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008, 659(1-2):31-39.
31. Nguyen T, Nioi P, Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009, 284(20):13291-13295.
32. Li J, Ichikawa T, Janicki JS, Cui T: Targeting the Nrf2 pathway against cardiovascular disease. Expert Op Ther Targets 2009, 13(7):785-794.
33. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J: NRF2 and KEAP1 mutations: permanent resistance to chemotherapy in gallbladder cancer. J Gen Virol 2007, 88(9):2371-2380.
34. Kuhnel F, Zender L, Paul Y, Paul Y, Tietze MK, Trautwein C, Manns M, Kubicka S: NRF2 and KEAP1 mutations: permanent resistance to chemotherapy in gallbladder cancer. J Gen Virol 2007, 88(9):2371-2380.
35. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Ishimaru K, Kato T, Murayama Y, et al: NRF2 and KEAP1 mutations: permanent resistance to chemotherapy in gallbladder cancer. J Gen Virol 2007, 88(9):2371-2380.
36. Lincoln DT, Ali Emadi EM, Tomissin CF, Clarke FM: The thiorodoxin-thiorodoxin reductase system: over-expression in human cancer. Anticancer Res 2003, 23(38):2425-2433.
37. Pi J, Niu J, Li J, He Y, Stibilo M, Waikles MP: Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med 2008, 45(5):651-658.
38. Arner ES, Holmgren A: The thiorodoxin system in cancer. Semin Cancer Biol 2006, 16(6):420-426.
39. Sun Y, Rigas B: The thiorodoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008, 68(20):8269-8277.
40. Yoshikai A, Schreiber RA, Lee YT: Role of thiorodoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006, 8(1-12):2143-2151.
41. Tonissen KF, Di Trapani G: Thiorodoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 2009, 53(1):87-103.
42. Tan C, Gao P, Zheng Y, Yue W, Wang X, Jin H, Chen Q: Redox status of thiorodoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death. Cell Res 2008, 18(4):458-471.
43. Munoz M, Henderson M, Haber M, Norris M: Role of the MRPI/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007, 59(12):752-757.
44. Hodorova I, Rybarova S, Solar P, Vecanova J, Mihalik J, Bohus P, Melillo V, Ruchova D: Multidrug resistance proteins in renal cell carcinoma. Folia Biol (Praha) 2008, 54(4):187-192.
45. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34(4):378-390.
46. Sanchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, Castellon EA: Expression of multidrug resistance proteins in prostate cancer is related to cell sensitivity to chemotherapeutic drugs. Prostate 2009, 69(13):1448-1459.
47. van Brussel JP, Micksch GH: Multidrug resistance in prostate cancer. Onkologie 2003, 26(2):175-181.
48. Leslie EM, Haimer A, Waikles MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 2004, 279(31):32700-32708.
49. Tani C, Utsumi Y, Ueda T: Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance. Int J Hematol 2007, 85(1):26-31.
50. Liang XJ, Aszalos A: Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. J Biol Chem 2005, 280(11):11201-11202.
51. Kuhnel F, Tietze MK, Trautwein C, Manns M, Kubicka S: NRF2 and KEAP1 mutations: permanent resistance to chemotherapy in gallbladder cancer. J Gen Virol 2007, 88(9):2371-2380.
63. Sun XF, Zhang H: NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007, 22(12):1387-1398.

64. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK: Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J Cell Biochem 2002, 84(4):750-758.

65. Roussel RR, Barchowsky A: Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 2000, 377(1):204-212.

66. Fry RC, Navasumrit P, Valathan C, Svensson JP, Hogan BJ, Luo M, Bhattacharya S, Kandjanapa K, Soontararuks S, Nookabkaew S, et al: Activation of inflammation/NF-kappaB signaling in infants born to arsenic-exposed mothers. PLoS Genet 2007, 3(11):e207.

67. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE: Arsenic induces oxidant stress and NF-kappaB activation in cultured aortic endothelial cells. Free Radic Biol Med 1996, 21(6):783-796.

68. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, Dudek EJ: Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 1999, 159(1):65-75.

69. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC: Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci 2001, 61(2):283-294.

70. Huang C, Li J, Ding M, Wang L, Shi X, Castranova V, Vallyathan V, Ju G, Costa M: Arsenic-induced NFkappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001, 222(1-2):29-34.

71. Felix K, Manna SK, Wise K, Barr J, Ramesh GT: Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J Biochem Mol Toxicol 2005, 19(2):67-77.

72. Bode AM, Dong Z: The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 2002, 42(1):5-24.

73. Chen F, Ding M, Castranova V, Shi X: Carcinogenic metals and NF-kappaB activation. Mol Cell Biochem 2001, 222(1-2):159-171.

74. Kumagai Y, Sumi D: Arsenic: Signal Transduction, Transcription Factor, and Biotransformation Involved in Cellular Response and Toxicity. Annu Rev Pharmacol Toxicol 2006.

75. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidenreit C, Bommert K: Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003, 102(3):1028-1034.

76. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong AN: Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008, 76(11):1485-1489.

77. Nair S, Doh ST, Chan JY, Yang AN, Cai L: Regulatory potential for concerted modulation of Nrf2- and NfkappaB-mediated gene expression in inflammation and carcinogenesis. Br J Cancer 2008, 99(12):2070-2082.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/10.1186/1755-8794-3-37

DOI: 10.1186/1755-8794-3-37

Cite this article as: Liu et al.: The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Medical Genomics 2010 3:37.